As sargramostim is known to restore HLA-DR expression in post-surgery patients and sepsis-associated immunosuppression (as mentioned in Immune responses to infections and risk of GM-CSF insufficiency (65, 217), this receptor might become a clinically useful wound healing biomarker. Here, CSF2 is linked to Sepsis.